Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit
Source: SeekingAlpha
2026-03-04 06:57:42 ET
More on Sanofi, Sino Biopharmaceutical Limited
- Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
- Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
- Sanofi 2025 Q4 - Results - Earnings Call Presentation
- Sanofi replaces CEO Paul Hudson, names Belén Garijo as successor
- Sanofi anticipates profitable growth to continue over at least five years
Read the full article on Seeking Alpha
For further details see:
Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit
Sanofi
NASDAQ: SNYNF
SNYNF Trading
-0.56% G/L:
$88 Last:
363 Volume:
$88 Open:
SNYNF Latest News
March 05, 2026 03:16:37 am
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
March 04, 2026 12:30:40 pm
Press Release: Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report
March 02, 2026 01:00:00 am
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
SNYNF Stock Data
$121,583,170,304
1,228,540,835
N/A
1460
N/A
Pharmaceuticals
Healthcare
FR
Paris
